🔗 Share this article

The Nobel Prize in Physiology or Medicine was granted for revolutionary findings that illuminate how the body's defense network targets dangerous pathogens while protecting the healthy tissues.

Three esteemed researchers—Japan's Shimon Sakaguchi and US experts Mary Brunkow and Fred Ramsdell—received this accolade.

The work identified unique "sentinels" within the immune system that eliminate malfunctioning immune cells capable of harming the organism.

These findings are now enabling innovative therapies for autoimmune diseases and cancer.

The winners will divide a monetary award valued at 11 million SEK.

Decisive Findings

"The research has been essential for comprehending how the immune system functions and the reason we don't all develop severe self-attack conditions," commented the chair of the award panel.

This trio's research explain a fundamental mystery: How does the immune system defend us from countless infections while leaving our own tissues intact?

The immune system employs white blood cells that scan for signs of disease, including pathogens and bacteria it has not met before.

These cells utilize detectors—known as recognition units—that are produced randomly in countless combinations.

That provides the immune system the capacity to fight a wide array of invaders, but the randomness of the process inevitably produces immune cells that can target the host.

Protectors of the Body

Scientists earlier understood that a portion of these harmful defense cells were destroyed in the immune organ—where white blood cells develop.

This year's Nobel Prize honors the identification of regulatory T-cells—described as the body's "peacekeepers"—which patrol the body to disarm any defenders that assault the body's own tissues.

We know that this mechanism malfunctions in self-attack conditions such as type-1 diabetes, MS, and RA.

A prize committee stated, "These findings have laid the foundation for a new field of investigation and spurred the development of new treatments, for instance for tumors and immune disorders."

In malignancies, regulatory T-cells block the system from attacking the tumor, so studies are aimed at reducing their quantity.

For autoimmune diseases, experiments are testing boosting T-reg cells so the body is no longer under attack. A comparable approach could also be useful in minimizing the chances of organ transplant failure.

Pioneering Experiments

Professor Sakaguchi, from a Japanese institution, performed tests on rodents that had their immune gland removed, causing self-attack conditions.

He demonstrated that introducing defense cells from healthy mice could stop the disease—implying there was a system for blocking defenders from harming the body.

Mary Brunkow, affiliated with the a research center in a US city, and Fred Ramsdell, currently at a biotech firm in San Francisco, were studying an genetic autoimmune disease in rodents and humans that resulted in the identification of a gene critical for how T-regs operate.

"Their groundbreaking research has revealed how the immune system is controlled by regulatory T cells, preventing it from accidentally targeting the body's own tissues," said a leading biological science specialist.

"This work is a remarkable illustration of how fundamental biological study can have far-reaching implications for public health."